COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis.
COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis.
复制标题
DOI：
10.1016/j.eclinm.2021.100789
复制
发表时间：
2021-03
影响因子：
15.1
通讯作者：
Sin DD
中科院分区：
文献类型：
--
作者：
Gerayeli FV;Milne S;Cheung C;Li X;Yang CWT;Tam A;Choi LH;Bae A;Sin DD
慢性阻塞性肺病（COPD）患者极易因病毒性呼吸道感染而导致呼吸道症状加重。然而，尚不清楚他们患 COVID-19 肺炎或与 COVID-19 相关的死亡的风险是否增加。我们的目的是确定 COPD 是否是导致 COVID-19 不良结局（包括住院、重症 COVID-19 或死亡）的危险因素。根据 PRISMA 指南，我们对 2019 年 11 月 1 日至 2021 年 1 月 28 日期间发表的 COVID-19 临床研究进行了系统回顾（PROSPERO ID：CRD42020191491）。我们纳入了量化 COPD 患者数量的研究，并报告了按 COPD 状态分层的以下至少一项结局：住院治疗；严重的 COVID-19；入住 ICU；机械通气；急性呼吸窘迫综合征;或死亡率。我们对个别研究的结果进行荟萃分析，以确定 COPD 患者与非 COPD 患者的这些结果的比值比 (OR)。 59 项研究符合纳入标准，并进行了数据提取。大多数研究是住院患者的回顾性队列研究/病例系列。只有四项研究将 COPD 对 COVID-19 结局的影响作为主要终点。总体而言，COPD 与住院（OR 4.23，95% CI 3.65-4.90）、入住 ICU（OR 1.35，95% CI 1.02-1.78）和死亡率（OR 2.47，95% CI 2.18-2.79）的几率增加相关。临床诊断为 COPD 会显着增加 COVID-19 患者临床结果不佳的几率。因此，COPD 患者应被视为高危人群，并应采取预防措施和积极治疗 COVID-19（包括疫苗接种）。
Patients with chronic obstructive pulmonary disease (COPD) are highly susceptible from respiratory exacerbations from viral respiratory tract infections. However, it is unclear whether they are at increased risk of COVID-19 pneumonia or COVID-19-related mortality. We aimed to determine whether COPD is a risk factor for adverse COVID-19 outcomes including hospitalization, severe COVID-19, or death. Following the PRISMA guidelines, we performed a systematic review of COVID-19 clinical studies published between November 1st, 2019 and January 28th, 2021 (PROSPERO ID: CRD42020191491). We included studies that quantified the number of COPD patients, and reported at least one of the following outcomes stratified by COPD status: hospitalization; severe COVID-19; ICU admission; mechanical ventilation; acute respiratory distress syndrome; or mortality. We meta-analyzed the results of individual studies to determine the odds ratio (OR) of these outcomes in patients with COPD compared to those without COPD. Fifty-nine studies met the inclusion criteria, and underwent data extraction. Most studies were retrospective cohort studies/case series of hospitalized patients. Only four studies examined the effects of COPD on COVID-19 outcomes as their primary endpoint. In aggregate, COPD was associated with increased odds of hospitalization (OR 4.23, 95% confidence interval [CI] 3.65–4.90), ICU admission (OR 1.35, 95% CI 1.02–1.78), and mortality (OR 2.47, 95% CI 2.18–2.79). Having a clinical diagnosis of COPD significantly increases the odds of poor clinical outcomes in patients with COVID-19. COPD patients should thus be considered a high-risk group, and targeted for preventative measures and aggressive treatment for COVID-19 including vaccination.
登录
查看更多内容
DOI：
10.1016/j.jaip.2020.09.044
发表时间：
2021-01
期刊：
The journal of allergy and clinical immunology. In practice
影响因子：
--
作者：
Calmes D;Graff S;Maes N;Frix AN;Thys M;Bonhomme O;Berg J;Debruche M;Gester F;Henket M;Paulus V;Duysinx B;Heinen V;Dang DN;Paulus A;Quaedvlieg V;Vaillant F;Van Cauwenberge H;Malaise M;Gilbert A;Ghuysen A;Gillet P;Moutschen M;Misset B;Sibille A;Guiot J;Corhay JL;Louis R;Schleich F
通讯作者：
Schleich F
影响因子：
4.5
作者：
de la Rica, Roberto;Borges, Marcio;Gonzalez-Freire, Marta
通讯作者：
Gonzalez-Freire, Marta
DOI：
10.1164/rccm.202002-0445oc
发表时间：
2020-06-01
影响因子：
24.7
作者：
Feng, Yun;Ling, Yun;Qu, Jieming
通讯作者：
Qu, Jieming
DOI：
10.1016/s2213-2600(20)30370-2
发表时间：
2020-12
期刊：
The Lancet. Respiratory medicine
影响因子：
--
作者：
Grasselli G;Tonetti T;Protti A;Langer T;Girardis M;Bellani G;Laffey J;Carrafiello G;Carsana L;Rizzuto C;Zanella A;Scaravilli V;Pizzilli G;Grieco DL;Di Meglio L;de Pascale G;Lanza E;Monteduro F;Zompatori M;Filippini C;Locatelli F;Cecconi M;Fumagalli R;Nava S;Vincent JL;Antonelli M;Slutsky AS;Pesenti A;Ranieri VM;collaborators
通讯作者：
collaborators
影响因子：
24.3
作者：
Guan, Wei-jie;Liang, Wen-hua;He, Jian-xing
通讯作者：
He, Jian-xing